HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer.

Abstract
In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
AuthorsA Krarup-Hansen, E Andersen, K Elbaek, S N Rasmussen, M Dalmark
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 27 Issue 5 Pg. 521-5 ( 1988) ISSN: 0284-186X [Print] England
PMID3203009 (Publication Type: Journal Article)
Chemical References
  • Idarubicin
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Drug Evaluation
  • Female
  • Humans
  • Idarubicin (administration & dosage, adverse effects, pharmacokinetics)
  • Male
  • Middle Aged
  • Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: